Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Prevention of Progression in MGUS and SMM
NCT04850846Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), sponsored by Dana-Farber Cancer Institute. Started Apr 2021; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04850846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850846.